Aug, 2009

U.S.A.
News / Therapeutic Area News
New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy
MELVILLE, N.Y., Aug 01, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced further results from the Phase III SATURN study showing that Tarceva(R) (erlotinib)...
Read More

Jul, 2009

U.S.A.
News / Therapeutic Area News
New Data from Phase III SATURN Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif., Jul 13, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. today announced that SATURN, a pivotal Phase III study of...
Read More
U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces Acceptance of a Tarceva(R) Supplemental New Drug Application in Pancreatic Cancer for Review by the U.S. Food and Drug Administration; Tarceva's sNDA is Granted Priority Review Designation by the FDA
MELVILLE, N.Y.--(BUSINESS WIRE)--July 6, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the...
Read More
U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces Acceptance of a Tarceva(R) Supplemental New Drug Application in Pancreatic Cancer for Review by the U.S. Food and Drug Administration; Tarceva's sNDA is Granted Priority Review Designation by the FDA
MELVILLE, N.Y.--(BUSINESS WIRE)--July 6, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the...
Read More

Jun, 2009

U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces Acceptance of Tarceva Supplemental New Drug Application for Review by the U.S. Food and Drug Administration
MELVILLE, N.Y., Jun 15, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the...
Read More